ClinicalTrials.gg
Active, not recruitingNCT05608837LEOPARDUpdated Nov 2, 2026

Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema

A Phase 2 interventional study of OCS-01 in Uveitis Related Cystoid Macular Edema and Cystoid Macular Edema, Postoperative, sponsored by Quan Dong Nguyen. Active, not recruiting at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Quan Dong Nguyen · Phase 2, Interventional, and Treatment

How we know

Updated Nov 2, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 276 studies in Macular Edema with a site in United States — 16 open to participants now, 32 under way, 11 of them phase 3. Macular Edema · United States.

Enrollment
150th of 244
28 · median 45
Started
2023
with 10 others
Phase 2
63 of 276
3 open now
Primary completion
2026-10
later than 8 of 31 live
Registered
234th of 276
by date

Among the 276 studies in Macular Edema with a site in United States, this one is the 150th largest by enrollment of the 244 interventional ones that give a count, is one of 11 that started in 2023, is one of 63 in phase 2, reaches primary completion later than 8 of the 31 other live ones, and was the 234th registered.

Macular Edema

759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

16 of the 276 studies in Macular Edema with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Macular Edema with a site in United States, or all of them as a file.
02

Study summary

The goal of the LEOPARD clinical trial is to investigate a new kind of steroid eye drops, OCS-01.

Macular edema is a condition in which there is collection of fluid (edema) in the back of the eye (Macula) and it can lead to severe loss of vision. Among other causes, macular edema can happen because of a disease of the eye called Uveitis, and also after eye surgery. Treatment of macular edema remains a challenge as the condition may persist for several months and may lead to irreversible changes in the eye and poor vision.

In the LEOPARD study the investigators wish to see how safe is the study drug (OCS-01) and how well it works, in resolving the fluid collection in the eye in patients with Uveitis or in patients who have had eye surgery.

Participants will undergo detailed eye exam, and record their eye and medical history to see what their disease status is and if they can be included in the study based on the study criteria. If included, they will take the study drug OCS-01 in different doses for 24 weeks. During the study period, they will have regular eye exams to ensure their safety and to assess the usefulness of the study drug.

Read the detailed description

LEOPARD is a prospective, multi-center, single masked, randomized, controlled, study. At least 24 eligible subjects (12 with Uveitic macular edema and 12 with Post surgical macular edema) are to be enrolled in the study. There will be at least 5 sites and the total treatment period is 24 weeks.

The study will consist of 4 phases: Screening Phase, Loading Phase, Treatment Phase and Follow-up Phase. Subjects will receive their assigned treatments until week 04, get randomized into groups and continue their assigned treatments until week 12. Primary endpoint assessments will be performed at week 12.

From week 12 to week 24, if there is still edema as demonstrated on OCT, subjects will receive treatment based on the retreatment criteria.

03

Conditions studied

  • Uveitis Related Cystoid Macular Edema
  • Cystoid Macular Edema, Postoperative

Keywords

  • Cystoid Macular Edema
  • Uveitis
  • Postoperative cystoid macular edema
  • Dexamethasone
  • Retinal diseases
  • Anti-Inflammatory Agents
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or older.
  2. Diagnosis of Uveitic macular edema (UME) or post-surgical macular edema (PSME).
  3. Can provide written prior to any study procedure being performed, able and willing to follow all instructions, and attend all study visits.
  4. UME of less than 1 years in duration or PSME of less than 1 year, with presence of intraretinal and/or subretinal fluid in the study eye, with CST of ≥ 320 µm by SD-OCT at baseline (as measured by the central reading center employing Heidelberg Spectralis spectral domain optical coherence tomography, SD-OCT). Note: Recurrent CME is also eligible if the current episode is of less than 1 year.
  5. An ETDRS BCVA letter score ≤ 70 (Snellen 20/40) and ≥ 35 (Snellen 20/200) in the study eye at baseline (Visit 2).
  6. A documented diagnosis of inactive/stable uveitis (for UME) at the screening visit.
  7. A trial of topical NSAID or topical (for PSME) for at least one consecutive month but less than 3 consecutive months before screening visit with documented treatment failure on SD-OCT or based on investigator's clinical evaluation.

Note: If both eyes are eligible, the eye with the worse BCVA will be selected as the study eye. If both eyes have the same BCVA, the non-dominant eye will be selected.

Exclusion criteria

Exclusion Criteria:

Subjects who meet any of the following exclusion criteria will not be included in the study

  1. Macular edema considered to be due to a cause other than UME or PSME. An eye is not considered eligible if: (1) the macular edema is considered to be related to diabetes (2) clinical exam and/or OCT suggests that vitreoretinal interface abnormalities (e.g., a taut posterior hyaloid or epiretinal membrane) are the primary cause of the macular edema, or (3) the macular edema is considered to be related to another condition such as age-related macular degeneration, retinal vein occlusion, or drug toxicity.
  2. A decrease in BCVA due to causes other than UME or PSME (e.g., foveal atrophy, pigment abnormalities, dense subfoveal hard exudates, previous vitreoretinal surgery, central serous retinopathy, non-retinal condition, substantial cataract, macular ischemia) that are likely to decrease BCVA by 3 lines or more (i.e., cataract would be reducing acuity to 20/40 or worse if eye was otherwise normal).
  3. Use of other ophthalmic formulations during the study. However, intraocular pressure (IOP) lowering eye drops are allowed if they become necessary due to increased IOP.
  4. History of glaucoma and documented glaucomatous optic neuropathy or ocular hypertension in the opinion of the investigator, involving an IOP ≥ 25 mmHg on > 3 anti-glaucoma medications in the study eye.
  5. Any other ocular disease that could cause substantial reduction in BCVA, including retinal detachment, epiretinal membrane, vitreous hemorrhage or fibrosis involving the macula in the study eye, other retinal inflammatory or infectious diseases.
  6. Active peri-ocular or ocular infection (e.g., blepharitis, keratitis, scleritis, or conjunctivitis).
  7. History of infectious uveitis.
  8. High myopia (-8 diopter or more correction) in the study eye.
  9. Any form of diabetic retinopathy.
  10. History of increased intraocular pressure with topical therapy.
  11. Pregnancy/Breastfeeding

For UME:

  1. Active uveitis as determined by the presence of anterior chamber cells or vitreous cells.
  2. Unstable (increasing) dose of immunosuppressives during 2 months prior to the baseline visit. Immunosuppressives are defined as antimetabolites (methotrexate, mycophenolate mofetil, azathioprine, cyclosporine and tacrolimus, among others) and biologics (including adalimumab, infliximab, tocilizumab, golimumab, secukinumab and rituximab, and others).
  3. Treated with more than 2 types of immunosuppressives (excluding steroids) within 2 months prior to baseline visit.
  4. Unstable (increasing) dose of oral prednisone for 1 month before baseline visit.
  5. Oral prednisone therapy at dose > 10 mg daily (or equivalent) within 1 month prior to baseline visit.
  6. History of contact lens use within 2 weeks prior to baseline or at any time during the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    High Dose UME - 6 drops OCS-01

    From baseline until week 4 all participants will receive 01 drop of OCS-01, six times a day. At week 4, participants randomized to the high dose group will continue to receive 01 drop of OCS-01 six times a day until the primary end point at week 12. Starting week 12 the treatment will be administered based on the retreatment criteria until the end of study at week 24.

    Drug: OCS-01

  • Experimental
    Low Dose UME 3 drops OCS-01 and 3 drops Placebo

    From baseline until week 4 all participants will receive 01 drop of OCS-01, six times a day. At week 4, the participants randomized to low dose group will receive 01 drop of OCS-01 three times a day and 01 drop of placebo three times a day,( total 6 drops each day) until the primary end point at week 12. Starting week 12 the treatment will be administered based on the retreatment criteria until the end of study at week 24.

    Drug: OCS-01

  • Experimental
    High dose PSME - 6 drops of OCS-01

    From baseline until week 4 all participants will receive 01 drop of OCS-01, six times a day. At week 4, participants randomized to the high dose group will continue to receive 01 drop of OCS-01 six times a day until the primary end point at week 12. Starting week 12 the treatment will be administered based on the retreatment criteria until the end of study at week 24.

    Drug: OCS-01

  • Experimental
    Low dose PSME - 3 drops of OCS-01 and 3 drops of Placebo

    From baseline until week 4 all participants will receive 01 drop of OCS-01, six times a day. At week 4, the participants randomized to low dose group will receive 01 drop of OCS-01 three times a day and 01 drop of placebo three times a day, (total 6 drops each day) until the primary end point at week 12. Starting week 12 the treatment will be administered based on the retreatment criteria until the end of study at week 24.

    Drug: OCS-01

Interventions

  • DrugOCS-01

    One drop of OCS-01 eye drops, 3-6 times daily. Dosing frequency will depend on the phase of the study.

    Also known as: dexamethasone ophthalmic suspension eye drops

06

What researchers measure

Primary outcomes

  1. Central Subfield Thickness

    Mean change in central subfield thickness (CST) on optical coherence tomography (OCT) at week 12 compared to baseline.

    Time frame: Baseline to 12 weeks

  2. Visual Acuity

    Mean change in early treatment of diabetic retinopathy study (ETDRS) best corrected visual acuity (BCVA) letter score at week 12

    Time frame: Baseline to 12 weeks

Secondary outcomes

  1. Change in visual acuity

    Mean change in ETDRS BCVA letters at weeks 2, 4, 6, 8, 16, 20 and 24 compared to baseline.

    Time frame: Baseline to 24 weeks

  2. Change in visual acuity

    The percentage of subjects who gain ≥10 or ≥15 ETDRS letters at week 12 and 24 compared to baseline.

    Time frame: Week 12 and 24

  3. Central Subfield Thickness

    Mean change in CST as assessed by SD-OCT at weeks 2, 4, 6, 8, 16, 20, 24 compared to baseline.

    Time frame: Baseline to week 24

  4. Visual function and quality of life

    Improvement in quality of life as assessed by National Eye Institute Visual Function Questionnaire (NEI VFQ-25) at Week 12, and 24 compared to baseline.

    Time frame: Baseline, week 12 and week 24

  5. Change in macular leakage

    Percentage of subjects showing change in macular leakage on fluorescein angiography (FA) at week 12 and 24 compared to baseline

    Time frame: Baseline, week 12 and 24 weeks

Other outcomes

  1. Change in intraocular pressure from baseline

    Monitoring of intraocular pressure

    Time frame: 8, 12 and 24 weeks

  2. Change in BCVA

    Percentage of subjects who lose ≥15 ETDRS letters or more at weeks 8, 12, and 24 compared to baseline

    Time frame: Weeks 8, 12 and 24

  3. Adverse effects

    Participants will be directly asked at every visit during the drug exposure. In addition a contact number will be provided to the subjects to call if they experience any adverse affect or if they suspect adverse effect at any time between specific visits.

    Time frame: Weeks 8, 12 and 24

07

Study locations

8 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Oct 2026, 41 months after the start.

Of 50 phase 2 interventional studies under Macular Edema, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 32. This study's planned 41 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Jun 2026 → Oct 2026 and completion Sep 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2022
First posted
Nov 8, 2022
StartActual
May 26, 2023
Primary completionEst.
Oct 2026was Jun 2026
CompletionEst.
Oct 2026was Sep 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 2026→Oct 2026
Nov 2, 2026
Study completion
Sep 2026→Oct 2026
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Primary completion Jun 2026→Oct 2026
    Study completion Sep 2026→Oct 2026
    + 3 other changes: index terms, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05608837
Lead sponsor
Quan Dong Nguyen
Collaborators
Global Ophthalmic Research Center (GORC), Oculis
Responsible party
Quan Dong Nguyen (Professor of Ophthalmology, Stanford University) — Sponsor-investigator
First posted
Nov 8, 2022
Start date
May 26, 2023
Primary completion
Oct 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Nov 2, 2026

Study contacts

Quan D Nguyen, MD, MSc
study chair · Stanford University

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: OCS-01

Start the discussion